Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Brian Rosenzweig is co-chair of the firm’s Securities and Capital Markets Practice Group. He regularly represents private and public domestic and foreign companies as well as venture capital funds and investment banks in domestic and international capital-raising transactions.

Mr. Rosenzweig's practice predominantly involves capital markets transactions, including initial public offerings and follow-on equity offerings, for domestic and foreign private issuers in the life sciences, technology and financial services, industries. He also regularly represents emerging companies and venture capital funds focused on these industries.

Public Capital Raising

  • Represented BioNTech SE in connection with its July 2020 $511 million advanced follow-on offering and the related rights offering of American Depositary Shares.
  • Represented Uber Technologies, Inc. in connection with its US IPO on the New York Stock Exchange and its September 2020 issuance of $500 million of senior unsecured notes.
  • Represented the underwriters in the US IPO of Trevi Therapeutics, Inc., clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions.
  • Represented the underwriters in the US IPO and multiple follow-on offerings of ordinary shares of UroGen Pharma Ltd., an Israeli biopharmaceutical company focused on non-surgical treatments in uro-oncology.
  • Represented Lombard Medical, Inc., a UK-based medical device company focused on endovascular stent-grafts for the repair of aortic aneurysms, in its US IPO of ordinary shares.
  • Represented the underwriters in multiple public offerings of Repligen Corporation, a leading provider of advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs.
  • Represented the underwriters in the US IPO and a follow-on offering of American Depositary Shares of Nabriva Therapeutics AG, an Austria-based biopharmaceutical company focused on developing a new class of antibiotics.
  • Represented the underwriters in the US IPO and a follow-on offering of ordinary shares of Affimed N.V., a German-based biotechnology company focused on immuno-oncology.
  • Represented Darwin Professional Underwriters Inc., a specialty insurance group focused on the professional liability insurance market, in its US IPO.
  • Represented the underwriters in the US IPO and a follow-on offering of ordinary shares of uniQure N.V., an Amsterdam-based gene therapy company.

Private Capital Raising / Emerging Companies / Venture Capital

  • Represented venture capital fund RTW Investments in multiple investments, including cross-over rounds,in private life sciences companies.
  • Represented BioNTech SE in a $50 million private placement of ordinary shares to Fosun Pharma, a $113 million private placement of ordinary shares to Pfizer, and a $251 million private placement of ordinary shares and a convertible note to Temasek.
  • Represented Knoema Corporation, an emerging private company that provides an end-to-end data and knowledge management platform in the acquisition of Adaptive Management, an alternative data aggregator and solutions provider.
  • Chambers USA, Capital Markets: Debt & Equity (2017-2020)
  • Legal 500 US, Capital Markets: Equity Offerings (2016)
  • New York Super Lawyers “Rising Star” (2014-2018)